Wiener klinische Wochenschrift

, Volume 122, Issue 13–14, pp 413–422 | Cite as

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

  • Yuqin Li
  • Xiayue Huang
  • Linhua Yao
  • Ruihua Shi
  • Guoxin ZhangEmail author
Original article


OBJECTIVE: The main aim of this meta-analysis was to compare the efficacy and safety of clarithromycin and second-generation fluoroquinolone-based triple therapy vs. bismuth-based quadruple therapy for the treatment of persistent Helicobacter pylori infection. METHODS: A systematic literature search was conducted for articles and abstracts from 1981 to March 2009 using Medline, PubMed, EMBase, Google Scholar and CNKI (Chinese), Wanfang (Chinese) digital database and recent Digestive Disease Week, United European Gastroenterology Week, and European Helicobacter Study Group conferences were also performed. Boolean operators (NOT, AND, OR) were used in succession to narrow and widen the search. Sixteen articles and four abstracts met the inclusion criteria, and were included in the meta-analysis by using Review Manager 4.2.8. RESULTS: The eradication rates demonstrated that clarithromycin-based triple therapy is inferior to bismuth-based quadruple therapy (OR = 0.53, 95% CI: 0.35–0.80, P = 0.002). Thirteen RCTs compared levofloxacin-based triple therapy vs. bismuth-based quadruple therapy, the eradication rates of the two regimens were shown to have no significant difference (OR = 1.43, 95% CI: 0.82–2.51, P = 0.21). But the eradication rates demonstrated superiority of the 10-day levofloxacin-based triple therapy over 7-day bismuth-based quadruple therapy (OR = 4.79, 95% CI: 2.95–7.79, P < 0.00001). Levofloxacin-based triple therapy was better tolerated than bismuth-based quadruple therapy with lower rates of side effects (OR = 0.41, 95% CI: 0.27–0.61, P < 0.0001), and lower rates of discontinuation of therapy due to adverse events (OR = 0.13, 95% CI: 0.06–0.33, P < 0.0001). Furthermore, our meta-analysis suggested that the eradication rates of the moxifloxacin-based triple therapy has a slight superiority to bismuth-based quadruple therapy, but there was no significant difference between them. CONCLUSION: Second-generation fluoroquinolone-based triple therapy can be suggested as the regimen of choice for rescue therapy in the eradication of persistent H. pylori infection especially 10-day levofloxacin-based triple therapy.


PPI Bismuth Levofloxacin Moxifloxacin Fluoroquinolone Helicobacter Eradication rate Second-line treatment 

Vorteile einer Moxifloxazin beziehungsweise Laevofloxazin basierten Triple Therapie als Second-line Behandlung einer persistenten Infektion mit Helicobacter pylori: Eine Metaanalyse


ZIEL: Das wesentliche Ziel der vorliegenden Meta Analyse war es, die Wirksamkeit und Sicherheit einer Therapie einer persistierenden Helicobacter pylori Infektion mit entweder einer Clarithromycin und 2. Generation Fluorquinolon-basierten Tripel Therapie mit einer Bismuth basierten Quadrupel Therapie zu vergleichen. METHODIK: Es wurde eine systematische Literatur Recherche nach Artikel und Abstracts des Zeitraums 1981–2009 durchgeführt. Durchforstet wurden Medline, PubMed, EMBase, Google Scholar sowie CNKI (chinesisch), Wanfang (chinesisch) Digital Database und recent Digestive Disease Week, United European Gastroenterology Week sowie Konferenzen der European Helicobacter Study Group. Die stufenweise Einengung oder Erweiterung der Recherche erfolgte durch Boolean operators (NOT, AND, OR). 16 Artikel und 4 Abstracts erfüllten die Einschlusskriterien und wurden in die Meta Analyse (Review Manager 4.2.8) einbezogen. ERGEBNISSE: Die berichteten Eradikationsraten zeigten, dass die Clarithromycin basierte Triple Therapie der Bismuth basierten Quadrupel Therapie unterlegen zu sein scheint (OR = 0,53; 95 % CI: 0,35–0,80; P = 0,002). 13 RCTs verglichen eine Laevofloxacin basierte Triple Therapie mit einer Bismuth basierten Quadrupel Therapie – diese 2 Therapiearten unterschieden sich bezüglich ihres Eradikationserfolges nicht signifikant (OR = 1,43; 95 % CI: 0,82–2,51; P = 0,21). Allerdings waren die Eradikationsraten der 10-tägigen Laevofloxacin basierte Triple Therapie einer 7tägigen Bismuth basierten Quadrupel Therapie signifikant überlegen (OR = 4,79; 95 % CI: 2,95–7,79; P < 0,00001). Die Laevofloxacin basierte Tripel Therapie wurde besser vertragen als die Bismuth basierte Quadrupel Therapie (OR = 0,41; 95 % CI: 0,27–0,61; P < 0,0001) und musste auch seltener wegen Nebenwirkungen abgebrochen werden (OR = 0,13; 95 % CI: 0,06–0,33; P < 0,0001). Außerdem lässt das Ergebnis unserer Meta Analyse vermuten, dass die Eradiaktionsraten der Moxifloxacin-basierten Tripel Therapie der Bismuth basierten Quadrupel Therapie geringfügig – allerdings ohne statistische Signifikanz – überlegen ist. SCHLUSSFOLGERUNG: Eine 2. Generation Fluoroquinolon- basierte Tripel Therapie – vor allem das 10tägige Regime mit Laevofloxacin – kann als Behandlungsart 1. Wahl zur Eradikation einer persistierenden Helicobacter pylori Infektion empfohlen werden.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Buckley M, O'Morain C (1995) Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Aliment Pharmacol Ther 9[Suppl 2]: 53–8 [PMID:8547529]PubMedGoogle Scholar
  2. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311–5 [PMID:6145023]CrossRefPubMedGoogle Scholar
  3. Marshall BJ, Windsor HM (2005) The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology epidemiology, screening clinical presentation treatment, and prevention. Med Clin North Am 89: 313–44 [PMID:15656929]CrossRefPubMedGoogle Scholar
  4. Graham DY, Lu H, Yamaoka Y (2007) A report card to grade Helicobacter pylori therapy [Editorial]. Helicobacter 12: 275–8 [PMID:17669098]CrossRefPubMedGoogle Scholar
  5. Cristina L, Palazzuoli A, Giordano N (2006) H. pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. World J Gastroenterol 12(48): 7815–20Google Scholar
  6. Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, Koda K, Nomura S, Sugihara S, Shimomura T, Fujimoto TT, Oyashiki K, Ikeda Y (2005) Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 81(2): 162–8 [PMID:15765787]CrossRefPubMedGoogle Scholar
  7. Grande M, Cadeddu F, Villa M, Attinà GM, Muzi MG, Nigro C, Rulli F, Farinon AM (2008) Helicobacter pylori and gastroesophageal reflux disease. World J Surg Oncol 6: 74 [PMID:18601740]CrossRefPubMedGoogle Scholar
  8. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, et al (1992) Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 116: 705–8 [PMID:1558340]PubMedGoogle Scholar
  9. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56(6): 772–81 [PMID:17170018]CrossRefPubMedGoogle Scholar
  10. Gisbert JP (2008) "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 14(35): 5385–402 [PMID:18803350]CrossRefPubMedGoogle Scholar
  11. Mégraud F (2004) H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53: 1374–84 [PMID:15306603]CrossRefPubMedGoogle Scholar
  12. Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F (2003) Risk factors for failure of Helicobacter pylori therapy – results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 17: 99–109 [PMID:12492738]CrossRefPubMedGoogle Scholar
  13. Malfertheiner P, Megraud F, O'Morain C, et al (2002) Current concepts in the management of Helicobacter pylori infection – The Maastricht 2 – 2000 Consensus Report. Aliment Pharmacol Ther 16: 167–80 [PMID:11860399]CrossRefPubMedGoogle Scholar
  14. Saad RJ, Schoenfeld P, Kim HM, Chey WD (2006) Levofloxacin-based triple therapy versus Bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 101(3): 488–96 [PMID:16542284]CrossRefPubMedGoogle Scholar
  15. Chey WD, Wong BC (2007) Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102: 1808–25 [PMID:17608775]CrossRefPubMedGoogle Scholar
  16. Gisbert JP, Morena F (2006) Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 23(1): 35–44 [PMID:16393278]CrossRefPubMedGoogle Scholar
  17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1–12 [PMID:8721797]CrossRefPubMedGoogle Scholar
  18. Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC (2009) Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 63(5): 1017–24 [PMID:19246508]CrossRefPubMedGoogle Scholar
  19. Jung HS, Shim KN, Baik SJ, Na YJ, Kang MJ, Jung JM, Ha CY, Jung SA, Yoo K (2008) Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication. Korean J Gastroenterol 51(5): 285–90 [PMID:18516012] (abstracts in English, full articles in Korean)PubMedGoogle Scholar
  20. Zhang H, Yu J, Jia CH (2008) Rescue regimen after Helicobacter pylori eradication failure with triple therapy. Chin J Clin Pharmacol 24(4): 361–3Google Scholar
  21. Liang ZG, Quan HB, He SZ (2007) Clinical research on levofloxacin-based therapy curing Helicobacter pylori as a salvage treatment. Hai Nan Yi Xue 18: 1–3Google Scholar
  22. Zhang Y, Wu J, Jia YG (2007) Observation on effect of levofloxacin-based therapy as a salvage therapy to Helicobacter pylori. Chin J Dig 19: 320–1Google Scholar
  23. Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS, Chan AO, Lai KC, Chan CK, Wong BC (2006) Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 23(3): 421–7 [PMID:16423001]CrossRefPubMedGoogle Scholar
  24. Nista EC, Candelli M, Santoro M, et al (2005) Levofloxacin-base triple therapy in second-line treatment for H. pylori eradication: Update. Gastroenterology 128: A-63Google Scholar
  25. Wong WM, Chu KM, Yee YK, et al (2004) Randomized controlled trial of lansoprazole, levofloxacin and amoxycillin triple therapy versus lansoprazole-based quadruple therapy as a rescue treatment after failure of Helicobacter pylori (H. pylori) eradication with standard triple therapies. Gut 53[Suppl VI]: A-124Google Scholar
  26. Nista EC, Candelli M, Fini L, et al (2004) 10 days levofloxacin-based triple therapy in second-line treatment for Helicobacter pylori eradication. Gastroenterology 126[4 Suppl 2]: A-74Google Scholar
  27. Bilardi C, Dulbecco P, Zentilin P, Reglioni S, Iiritano E, Parodi A, Accornero L, Savarino E, Mansi C, Mamone M, Vigneri S, Savarino V (2004) A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2(11): 997–1002 [PMID:15551252]CrossRefPubMedGoogle Scholar
  28. Wong WM, Gu Q, Lam SK, Fung FM, Lai KC, Hu WH, Yee YK, Chan CK, Xia HH, Yuen MF, Wong BC (2003) Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 17(4): 553–60 [PMID:12622764]CrossRefPubMedGoogle Scholar
  29. Perri F, Festa V, Merla A, Barberani F, Pilotto A, Andriulli A (2003) Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 18(8): 815–20 [PMID:14535875]CrossRefPubMedGoogle Scholar
  30. Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M, Santarelli L, Zocco MA, Ojetti V, Carloni E, Cammarota G, Gasbarrini G, Gasbarrini A (2003) Levofloxacin-based triple therapy vs quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 18(6): 627–33 [PMID:12969089]CrossRefPubMedGoogle Scholar
  31. Kang JM, Kim N, Lee DH, Park YS, Kim YR, Kim JS, Jung HC, Song IS (2007) Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 12(6): 623–8 [PMID:18001404]PubMedGoogle Scholar
  32. Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS (2006) Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 11(1): 46–51 [PMID:16423089]CrossRefPubMedGoogle Scholar
  33. Bago J, Pevec B, Tomić M, Marusić M, Bakula V, Bago P (2009) Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 121(1–2): 47–52 [PMID:19263014]CrossRefPubMedGoogle Scholar
  34. Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, Stolte M, Börsch G, Labenz J, Malfertheiner P (2002) High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 16(2): 315–24 [PMID:11860415]CrossRefPubMedGoogle Scholar
  35. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C (2005) Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 21: 91–6 [PMID:15644050]CrossRefPubMedGoogle Scholar
  36. Peitz U, Sulliga M, Nusch A, Wolle K, Leodolter A, Stolte M, Borsch G, Labenz J, Malfertheiner P (1998) Randomised study on the impact of resistance on second-line treatment after failed metronidazole-clarithromycin containing triple therapy. Gut 43(2S) [Suppl]: 82A–3AGoogle Scholar
  37. Mantzaris GJ, Petraki C, Petraki K, Roussos A, Karagiannidis A, Christidou A, Christoforidis P, Polyzou P, Koilakou S, Triantafyllou G (2005) Prospective, randomized study of seven versus fourteen days omeprazole quadruple therapy for eradication of Helicobacter pylori infection in patients with duodenal ulcer after failure of omeprazole triple therapy. Ann Gastroenterol 18(3): 330–5Google Scholar
  38. Vakil N, Vaira D (2008) Sequential therapy for Helicobacter pylori: time to consider making the switch? JAMA 300: 1346–7 [PMID:18799448]CrossRefPubMedGoogle Scholar
  39. Vakil N, Megraud F (2007) Eradication therapy for Helicobacter pylori. Gastroenterology 133(3): 985–1001 [PMID:17854602]CrossRefPubMedGoogle Scholar
  40. Marshall B, MD (2008) Sequential therapy for Helicobacter pylori: a worthwhile effort for your patients. Ann Intern Med 148: 962–3 [PMID:18490666]PubMedGoogle Scholar
  41. De Francesco V, Margiotta M, Zullo A (2006) Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 144: 94–100 [PMID:16418408]PubMedGoogle Scholar
  42. Owen RJ (2002) Molecular testing for antibiotic resistance in Helicobacter pylori. Gut 50: 285–9 [PMID:11839700]CrossRefPubMedGoogle Scholar
  43. van Doorn LJ, Glupczynski Y, Kusters JG, Mégraud F, Midolo P, Maggi Solcà N, et al (2001) Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother 45: 1500–4 [PMID:11302817]CrossRefPubMedGoogle Scholar
  44. Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, et al (1997) Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 40: 283–6 [PMID:9301997]CrossRefPubMedGoogle Scholar
  45. Kaneko F, Suzuki H, Hasegawa N, Kurabayshi K, Saito H, Otani S, et al (2004) High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. Aliment Pharmacol Ther 20[Suppl 1]: 62–7 [PMID:15298607]CrossRefPubMedGoogle Scholar
  46. Masaoka T, SuzukiKurabayashi HK, Kamiya AG, Ishii H (2004) Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment Pharmacol Ther 20[Suppl 1]: 68–73 [PMID:15298608]CrossRefPubMedGoogle Scholar
  47. de Boer W, Driessen W, Jansz A, Tytgat G (1995) Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 345: 817–20CrossRefPubMedGoogle Scholar
  48. de Boer W, Driessen WM, Potters VP, Tytgat GN (1994) Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 89: 1993–7PubMedGoogle Scholar
  49. de Boer W, Tytgat GN (1995) 90% cure: which anti-Helicobacter therapy can achieve this treatment goal? Am J Gastroenterol 90: 1381–2PubMedGoogle Scholar
  50. de Boer W, van Etten RJ, Lai JY, Schneeberger PM, van de Wouw BA, Driessen WM (1996) Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. Helicobacter 1: 145–50CrossRefPubMedGoogle Scholar
  51. de Boer W (1996) How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 22: 313–6CrossRefPubMedGoogle Scholar
  52. de Boer W, van Etten RJ, van de Wouw BA, Schneeberger PM, Van Oijen AH, Jansen JB (2000) Bismuth-based quadruple therapy for Helicobacter pylori – a single triple capsule plus lansoprazole. Aliment Pharmacol Ther 14: 85–9CrossRefPubMedGoogle Scholar
  53. Gisbert JP, Pajares JM (2002) Helicobacter pylori rescue regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 16(6): 1047–57 [PMID:12030945]CrossRefPubMedGoogle Scholar
  54. Croom KF, Goa KL (2003) Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63: 2769–802 [PMID:14664657]CrossRefPubMedGoogle Scholar
  55. Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A (2006) Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 101: 1985–90 [PMID:16968503]CrossRefPubMedGoogle Scholar
  56. Gisbert JP, Castro-Fernandez M, Bermejo F, et al (2006) Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 101: 243–7CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yuqin Li
    • 1
  • Xiayue Huang
    • 1
  • Linhua Yao
    • 1
  • Ruihua Shi
    • 1
  • Guoxin Zhang
    • 1
    Email author
  1. 1.Department of GastroenterologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina

Personalised recommendations